Figures & data
Table 1. Marginal vaccine effectiveness against SARS-CoV-2 infection relative to BNT162b2 primary vaccination.
Supplemental material
Emerging Microbes & Infections
Volume 11, 2022 - Issue 1
Coronaviruses
Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
Jing Lian Suaha Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia
https://orcid.org/0000-0003-0908-3597
https://orcid.org/0000-0003-0908-3597, , Peter Seah Keng Toka Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysiahttps://orcid.org/0000-0003-3663-450X
https://orcid.org/0000-0003-3663-450X, Masliyana Husina Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysiahttps://orcid.org/0000-0002-6553-6012
https://orcid.org/0000-0002-6553-6012, , Kalaiarasu M. Peariasamya Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysiahttps://orcid.org/0000-0001-9279-3498
https://orcid.org/0000-0001-9279-3498 & Sheamini Sivasampua Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, MalaysiaCorrespondence[email protected]
https://orcid.org/0000-0003-2314-6048
https://orcid.org/0000-0003-2314-6048 show all